Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Medical Care : presents new strategy and announces new medium-term targets through 2025 at Capital Markets Day

10/09/2020 | 09:16am EST

Fresenius Medical Care, the world's leading provider of products and services for people with chronic kidney failure, is excellently positioned for continued, sustainable growth.

At today's virtual-only Capital Markets Day, management presented the company's new growth strategy and a new medium-term outlook for the coming five years to analysts and investors.

Fresenius Medical Care aims to much more closely mesh, over the entire path of the illness, the still highly fragmented treatments provided to chronic and critical kidney disease patients. For this purpose, the company will leverage even more effectively its core competencies in the innovation of products, operating outpatient facilities, standardizing medical procedures and efficiently coordinating patients.

The new strategy embraces three major areas. The first area, the Renal Care Continuum, puts dialysis products and services at its core and is enhanced by four components

New renal care models: Using digital technologies such as artificial intelligence and the capability to analyze huge amounts of data, Fresenius Medical Care is working to develop new forms of renal therapy. These include, for example, personalized medicine or holistic home care.

Value-based care: Drawing on its comprehensive experience in disease management, the company will push forward with the transition from a fee-for-service payment model to pay-for-performance models, in order to offer care that is even better and is also sustainably affordable.

Chronic kidney disease and transplantation: Fresenius Medical Care's offerings in the area of value-based care models will be expanded beyond dialysis to the treatment of chronic kidney disease as well as an active role in the area of kidney transplantation.

Renal care innovations: The company will continue to advance its development of renal care innovations and invest in start-ups and early-stage companies in the healthcare sector.

The second area is Critical care solutions. Fresenius Medical Care will extend its critical care portfolio to other extracorporeal intensive care therapy areas, such as the treatment of heart, lung and multi-organ failure.

The third area is Complementary assets. To leverage its existing network and create an additional basis for future growth, the company will further expand its network of complementary assets through partnerships, investments and acquisitions.

The new strategy is embedded in the company's Global Sustainability Program, which was launched last year. This program is under the direct responsibility of the Chief Executive Officer, and Management Board compensation will be oriented to it.

Together with the new strategy, Fresenius Medical Care is announcing a new medium-term outlook through 2025. During the next five years, in constant currency and excluding special items, the company expects annual average increases in the mid-single-digit percentage range for revenue and in the upper-single-digit percentage range for net income.

Rice Powell, Chief Executive Officer of Fresenius Medical Care, said during the opening of the Capital Markets Day: 'The new strategy is our next logical step. It's the next step up from our four core competencies, it's a step up for our network - and it's a step in our quest for even more valuable solutions for our patients as well as for payors and health care systems around the world.'

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,036 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 347,683 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).


This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.


Matthias Link

Tel: +49 6172 609-2872

Email: matthias.link@fmc-ag.com

(C) 2020 Electronic News Publishing, source ENP Newswire

11/30FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 41 of the Wp..
11/27Swiss drugmaker Vifor had bid interest but talks halted - sources
11/24FRESENIUS SE : UBS remains Neutral
11/19FMC FRESENIUS MEDICAL CARE AG & CO K : RBC reiterates its Neutral rating
11/19FMC FRESENIUS MEDICAL CARE AG & CO K : Bernstein reiterates its Neutral rating
11/19FRESENIUS SE : Bernstein reiterates its Buy rating
11/17FMC FRESENIUS MEDICAL CARE AG & CO K : Jefferies reiterates its Neutral rating
11/16FRESENIUS MEDICAL CARE : included for 11th time in Dow Jones Sustainability Inde..
11/13FRESENIUS SE : Receives a Buy rating from Bernstein
11/12FMC FRESENIUS MEDICAL CARE AG & CO K : Gets a Neutral rating from Bernstein
More news
Financials (USD)
Sales 2020 21 231 M - -
Net income 2020 1 532 M - -
Net Debt 2020 15 175 M - -
P/E ratio 2020 16,5x
Yield 2020 1,63%
Capitalization 25 013 M 24 977 M -
EV / Sales 2020 1,89x
EV / Sales 2021 1,75x
Nbr of Employees 126 463
Free-Float 65,1%
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 95,34 $
Last Close Price 85,42 $
Spread / Highest target 31,2%
Spread / Average Target 11,6%
Spread / Lowest Target -25,6%
EPS Revisions
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer